ipilimumab - Robuta Search

https://researchers.westernsydney.edu.au/en/publications/ipilimumab-induced-toxicities-and-the-gastroenterologist/ Ipilimumab-induced toxicities and the gastroenterologist - Western Sydney University and the western sydney ipilimumab induced toxicities https://adisinsight.springer.com/trials/700239896?error=cookies_not_supported&code=ed478123-6a8a-48af-a85a-d331cf9dd822 A Phase II Open-Label Study of Ipilimumab Administered to Stage IIIC and Stage IV Melanoma Patients... This study was about to investigate the efficacy and tolerability of ipilimumab in patients with metastatic melanoma who have recently received (within 42 days) https://research.uni-luebeck.de/de/publications/combined-immunotherapy-with-nivolumab-and-ipilimumab-with-and-wit/ Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients... combined immunotherapy nivolumab https://www.pcpacanada.ca/fr/negotiation/20719 Yervoy (ipilimumab) | APP yervoy ipilimumab app https://www.bmsclinicaltrials.com/au/en/clinical-trials/NCT03215706 A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in... The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating... https://pubmed.ncbi.nlm.nih.gov/22271879/ CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma This report provides the longest follow-up of patients with melanoma treated with ipilimumab and shows that ipilimumab can induce durable, potentially curative... long term follow up https://www.iqwig.de/en/projects/a14-11.html [A14-11] Addendum to Commission A13-44 (ipilimumab, new therapeutic indication) Addendum to Commission A13-44 (ipilimumab, new therapeutic indication) addendum commission https://www.oncolink.org/treatment-binder/codes/lunni Lung - Nivolumab, Ipilimumab | OncoLink OncoLink, the Web's first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing... lung nivolumab ipilimumab https://www.jadpro.com/education/fda-focus/2025/opdivo-nivolumab-in-combination-with-yervoy-ipilimumab-for-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer/ JADPRO | Opdivo nivolumab in combination with Yervoy ipilimumab for unresectable or metastatic... https://pure.eur.nl/en/publications/rechallenge-of-ipilimumab-and-nivolumab-in-advanced-melanoma-pati/ Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous... advanced melanoma ipilimumab nivolumab https://www.colorectalcancercanada.com/drug/nivolumab-and-ipilimumab/ Nivolumab and ipilimumab - Colorectal Cancer Canada Indication First-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)... colorectal cancer nivolumab ipilimumab canada https://www.healthcareinternational.net/LatestNews/Interim_Phase_12_Data_Of_Ipilimumab_In_Prostate_Cancer_Presented_At_American_Society_Of_Clinical_Oncology_Annual_Meeting/ Health Care International - Latest News - Interim Phase 1/2 Data Of Ipilimumab In Prostate Cancer... Medarex, Inc. (Nasdaq: MEDX) announced interim results from a Phase 1/2 trial of ipilimumab, an investigational oncology immunotherapy, as monotherapy or in... https://adisinsight.springer.com/drugsafety/803883484?error=cookies_not_supported&code=8a550f12-7c8e-431a-9580-c09648b9333b COVID-19-vaccine/ipilimumab/nivolumab - AdisInsight A 47-year-old woman developed hypophysitis leading to hypoadrenalism and cerebral oedema during treatment with ipilimumab and nivolumab for malignant melanoma covid vaccine ipilimumab nivolumab adisinsight https://www.bmsstudyconnect.com/no/en/clinical-trials/NCT02714218.html A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects... The purpose of this study is to evaluate two different dose combinations of nivolumab and ipilimumab in the treatment of melanoma. https://www.genuinedrugs123.com/info/ipilimumab-yervoy-patient-information-leaflet-in-chinese Ipilimumab Yervoy - Patient Information Leaflet in Chinese Ipilimumab Yervoy - See Medication Guide as developed by the manufacturer, approved by the FDA, and translated in Chinese for Patient Use and Reference,... patient information leaflet ipilimumab yervoy chinese https://www.bmsclinicaltrials.com/au/en/clinical-trials/NCT02872116 Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in... The main purpose of this study is to compare how long patients with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab... efficacy study nivolumab plus ipilimumab chemotherapy https://adisinsight.springer.com/drugsafety/803431966?error=cookies_not_supported&code=c35584bc-b0fe-4580-be03-5f91299b80e2 Ipilimumab/nivolumab - AdisInsight A 77-year-old man developed autoimmune encephalitis during treatment with ipilimumab and nivolumab for stage IIIC mucosal melanoma.The man, who had stage IIIC ipilimumab nivolumab adisinsight https://www.cancernetwork.com/view/nivolumab-plus-ipilimumab-offers-improved-survival-outcomes-certain-metastatic-crc-patients Nivolumab Plus Ipilimumab Offers Improved Survival Outcomes in Certain Metastatic CRC Patients |... May 11, 2026 - Patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer who received nivolumab along with ipilimumab had high... https://www.ispor.org/vih-articles/Volume-22--Supplemental-S3/PCN26-QUANTIFYING-THE-RELATIVE-CLINICAL-VALUE-OF-NIVOLUMAB-PLUS-IPILIMUMAB-VS--SUNITINIB-IN-FIRST-LINE-ADVANCED-OR-METASTATIC-RENAL-CELL-CARCINOMA-WITH-THE-NUMBER-NEEDED-TO-TREAT-AND-NUMBER-NEEDED-TO-HARM-IN-SPAIN-AND-PORTUGAL PCN26 QUANTIFYING THE RELATIVE CLINICAL VALUE OF NIVOLUMAB PLUS IPILIMUMAB VS. SUNITINIB IN... https://www.gecp.pt/abertura-de-pap-a-nivolumabipilimumab/ Abertura de PAP a nivolumab + ipilimumab abertura de pap nivolumab ipilimumab https://www.natera.com/resource-library/signatera/immunologic-signatures-of-response-and-resistance-to-nivolumab-with-ipilimumab-in-advanced-metastatic-cancer/ Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastati Tsimberidou AM, Alayli FA, Okrah K, et al. Journal of Experimental Medicine. 2024 https://open.library.emory.edu/concern/publications/c1df6893-5e5b-4006-a60c-5b4201fdba01?locale=en Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma... Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040... efficacy and safety https://adisinsight.springer.com/drugsafety/803106811?error=cookies_not_supported&code=b4600ca4-d102-4282-92dc-3f147e2d57b1 Ipilimumab - AdisInsight Two patients developed DRESS syndrome and acute granulomatous interstitial nephritis while receiving ipilimumab [routes not stated].A 78-year-old man had been ipilimumab adisinsight https://www.bmsstudyconnect.com/br/pt/clinical-trials/NCT02388906.html Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After... The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma. efficacy study compared to https://www.bmsstudyconnect.com/se/sv/clinical-trials/NCT02985957.html A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With... The purpose of this study is to determine whether nivolumab plus ipilimumab has preliminary evidence of safety and effectiveness in treatment of metastatic... https://survivingmesothelioma.com/nivolumab-plus-ipilimumab-has-best-survival-in-relapsed-mesothelioma/ Nivolumab plus ipilimumab Has Best Survival in Relapsed Mesothelioma May 28, 2022 - The drug combo nivolumab plus ipilimumab is the best second-line treatment in patients with relapsed malignant mesothelioma. nivolumab plus ipilimumab best survival